Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3

Several Anti-EGFR mAbs are register for the treatment of human cancer. However, their impact on patients overall survival has been limited by tumor resistance. N-Glycolyl variant of GM3 ganglioside (NGcGM3) is specifically expressed in some human tumors, and it has been associated with a poor progno...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomo, Addys González, Medinilla, Armando López, Segatori, Valeria, Barroso, María del Carmen, Blanco, Rances, Gabri, Mariano R., Pérez, Adriana Carr, Monzón, Kalet León
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963610/
https://www.ncbi.nlm.nih.gov/pubmed/29844873
http://dx.doi.org/10.18632/oncotarget.25290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963610/
https://www.ncbi.nlm.nih.gov/pubmed/29844873
http://dx.doi.org/10.18632/oncotarget.25290

Ejemplares similares